AiRNA Pharmaceuticals Frequently Asked Questions (FAQ)
Where is AiRNA Pharmaceuticals's headquarters?
AiRNA Pharmaceuticals's headquarters is located at Norwood.
Who are AiRNA Pharmaceuticals's competitors?
Competitors of AiRNA Pharmaceuticals include Reata Pharmaceuticals, VentiRx Pharmaceuticals, Theraclone Sciences, Bellicum Pharmaceuticals, GlycoMimetics and 12 more.
Compare AiRNA Pharmaceuticals to Competitors
Mimetogen is actively pursuing the development of novel small molecule compounds to treat neurodegenerative diseases of the eye, including dry eye, glaucoma and retinitis pigmentosa. The company designs and develops small molecule drugs that mimic the effects of neurotrophins, proteins that help maintain the health and growth of many cells and tissues found in the eye. Making drugs that can mimic the large natural molecules may lead to the development of novel approaches to treat degenerative ocular diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration and dry eye.
Novation is focusing on the development of small molecular weight drugs that affect the stability of messenger RNA. Initial development efforts are on the treatment and prevention of cancer and chronic inflammatory diseases.
ISA Pharmaceuticals develops treatments for various cancers and infectious diseases. It focuses on the development of synthetic peptide vaccines that boost the immune system to recognize specific peptides associated with specific types of cancer and subsequently destroy the tumor cells. The company was founded in 2004 and is based in Oestgeest, Netherlands.
Oxagen is a biopharmaceutical company that develops small molecule drugs for inflammatory and respiratory diseases.
MuriGen is building a portfolio of drugs for unmet medical needs across a number of therapeutic areas including cancer, arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia.
Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.